Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials

By sjmartinez • September 24, 2024

André F, Solovieff N, Su F, Bardia A, Neven P, Yap YS, Tripathy D, Lu YS, Slamon D, Chia S, Joshi M, Chakravartty A, Lteif A, Taran T, Arteaga CL. Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials. Ann Oncol. 2024 Sep 21:S0923-7534(24)04018-3. doi: 10.1016/j.annonc.2024.09.010. Epub ahead of print. PMID: 39313156.

Tags: acquired resistance, Advanced breast cancer, biomarkers, CDK4/6 inhibitor, Hematology/Oncology, Publications, ribociclib

Characterization of unique B-cell populations in the circulation of people living with HIV prior to non-Hodgkin lymphoma diagnosis

Martínez LE, Comin-Anduix B, Güemes-Aragon M, Ibarrondo J, Detels R, Mimiaga MJ, Epeldegui M. Characterization of unique B-cell populations in the circulation of people living[...]

Correlation of needle biopsy-acquired histopathologic grade of hepatocellular carcinoma with outcomes after thermal ablation

Chiang J, Raman SS, Ramakrishnan A, Keshavarz P, Sayre J, McWilliams JP, Finn RS, Agopian VG, Choi G, Lu DSK. Correlation of needle biopsy-acquired histopathologic[...]

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study

Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance AM, Daud[...]